arrow
A

Anikó Szabó

medical college of wisconsin
H指数:52
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

靶向CD38的双特异性抗体XmAb 18968在复发/难治性急性髓系白血病和T细胞急性淋巴细胞白血病患者中的应用

Leukemia
IF13.4
2026-09-140
PRE
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma

在复发/难治性多发性骨髓瘤的双特异性抗体治疗期间,淋巴细胞动力学和免疫组成的预后影响

2026-08-220
OAAI
TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

替达拉珠单抗在异基因造血干细胞移植后移植物抗宿主病的预防中的应用

2026-02-050
OAAI
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

优化肿瘤药物开发:22年多发性骨髓瘤随机对照试验的系统综述

2025-11-090
OAAI
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Talquetamab在复发难治性多发性骨髓瘤中的应用:多中心真实世界研究

2025-11-070
OAAI
Associations with resolution of ST-segment elevation myocardial infarction criteria on out-of-hospital 12-lead electrocardiograms following resuscitation from cardiac arrest

心脏骤停复苏后院外12导联心电图ST段抬高心肌梗死标准的消退关联性

2025-04-010
PRE
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

雷帕霉素抵抗性多克隆Th1/Tc1细胞疗法(RAPA-201)安全地诱导复发、难治性多发性骨髓瘤的疾病缓解。

2025-01-280
OA